Observational studyCancer2025

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Linda R Duska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.